Sanofi finally wins Genzyme deal
Submitted by Barinder Khatra on Wed, 02/16/2011 - 09:59Ending months of uncertainty, the Sanofi-Aventis deal with Genzyme finally came to an end since Sanofit was able to buy out Genzyme for $74 per share. This means that a total of $20.1 billion is going to be given as contingent value right and will bring to a halt the nine months of chase of the US biotech firm by French drugs' giant.
It is going to help Sanofi in controlling the falling revenues that are a result of several of its patents expiring and the cost that it has to bear for reshaping its business.
Spin-offs might possible show a ray of hope for Pfizer site
Submitted by Leonard Moore on Mon, 02/07/2011 - 07:52With the US maker Pfizer announcing the shutdown of its research and development site at Sandwich in Kent, the decision came as a blow this week as around 2,400 jobs are at risk.
The site, which has had remarkable success stories, was Pfizer's congregation for more than half a century. The site saw hits like the development of Viagra, the company's successful impotence drug, the Norvasc heart drug, and Celsentri, for HIV/Aids treatment.
Despite Q4 losses, GSK may buy back shares
Submitted by Barinder Khatra on Thu, 02/03/2011 - 12:39GlaxoSmithKline (GSK) Limited is expected to resume its share buyback programme on Thursday despite loss due to a massive legal charge in the fourth quarter. The investors who had urged GSK to adopt ‘giving cash back’ decision of other major drug companies would greatly welcome this move.
According to Thomson Reuters estimation the giant British drugmaker is believed to reveal its forecast to record a loss of around 6 pence a share in its 2010 results.
BTG to pay £160m for buying Biocompatibles
Submitted by Sunil Kumar on Fri, 11/19/2010 - 08:07The pharmaceutical group, renowned for its varisolve varicose veins treatment, BTG is going to add oncology products in its profile by capturing drug device group Biocompatibles, paying £160m.
The company will be paying premium of 28 pc on yesterday's Biocompatibles' share price thus taking the per share price to 430p and giving four-fold increase to the private investors having 10 percent shares in the company.
Novo Nordisk Plans to Discontinue Mixtard 30; Diabetics Concerned
Submitted by Gene Rickman on Mon, 11/01/2010 - 12:02Novo Nordisk has announced plans to drop Mixtard 30, an insulin drug, in order “to focus resources on developing the next generation of insulins”.
Mixtard 30 closely resembles insulin made naturally by the body, and is therefore known as human insulin. The new generation, called insulin analogues, have a different chemical make-up.
Dr. Anders Toft, Novo Nordisk’s UK Medical Director, says that Mixtard 30’s use is in decline. “There are several other preparations available which patients can switch to.”
Hikma Still has $500m to Spend on Expansion
Submitted by Barinder Khatra on Sun, 10/31/2010 - 12:20There are several procurements to be made by Hikma Pharmaceuticals as it still is said to have some $500m war chest to spend. It is said to have bought Baxter International's US drugs unit recently.
“You should see the big smile on my face. Our global injectables business has doubled in size overnight. We will see $180m worth of sales a year and our sales team will grow from eight to 28 people”, said Darwazah, Hikma's Chief Executive.
Pfizer Makes Another Recall
Submitted by Barinder Khatra on Sun, 10/31/2010 - 09:00Pfizer is reported to have widened the voluntary recall of its blockbuster cholesterol-fighting drug again. As per the company’s statement, an additional 38,000 bottles of the drug Lipitor have been recalled.
The decision emerged following reports that linked a "moldy or musty" odor with the packaging bottles, the Company highlighted. Pfizer had earlier given a recall for over 190,000 bottles of Lipitor because of similar kind of complaints.
Nuedexta Obtains FDA Approval; Avanir Shares More than Double
Submitted by Rasik Sharma on Sat, 10/30/2010 - 08:48The Food and Drug Administration (FDA) recently approved Nuedexta, a drug that will treat bouts of uncontrolled laughter or crying in patients with neurological disorders. Avanir Pharmaceuticals Inc., the drug's maker, saw its shares more than double in extended trading.
Teflaro gets FDA Approval for CABP and ABSSI Treatment
Submitted by Barinder Khatra on Sat, 10/30/2010 - 08:45On Friday, ceftaroline fosamil (Teflaro), manufactured by Forest Laboratories Inc. has been shown green signal by the Food and Drug Administration to provide treatment to adults suffering from community-acquired bacterial pneumonia (CABP) and other skin related infections such as acute bacterial skin and skin structure infections (ABSSSI) and methicillin-resistant Staphylococcus aureus (MRSA).
WeightWatchers Discard Outdated Diet Plan
Submitted by Rasik Sharma on Sat, 10/30/2010 - 07:41The development taking place everyday has made the international dieting Company, p change its fat and calorie-based points plan. They are now said to have adopted the new system since the old plan has come out to be inaccurate and outdated.
As per this new system, the main focus is being laid on the amounts and types of protein, carbohydrate, fibre and fat in food. According to speculation, it also permits alcohol and the odd fast food binge.
Thalidomide Victims initiate Class Action against Grunenthal GmbH
Submitted by Gene Rickman on Fri, 10/29/2010 - 10:32German pharmacy Company Grunenthal GmbH is now sued by the Victorian Supreme Court for distributing the drug thalidomide to pregnant Australian women whose children developed inabilities after being born.
A number of plaintiffs who represent the victims of the harming substance want the firm to take responsibilities for severe violations more than 50 years ago.
Quality Assurance Manager Rewarded for Whistleblowing
Submitted by Gene Rickman on Thu, 10/28/2010 - 07:59After the pharmaceutical Company GlaxoSmithKline PLC needed to reassess one of their manufacturing plants in Puerto Rico, they sent one of the Company’s quality assurance managers Cheryl Eckard. The former employee of the Company exposed severe abuses such as the production of a skin product for children that was poisonous.
Furthermore, Ms. Eckard observed that drugs often were mixed up in the same bottles in Puerto Rico, a dangerous mistake that has not been corrected.
Alternative Contraceptives Will Increase Women’s Options
Submitted by Rasik Sharma on Wed, 10/27/2010 - 08:08Pharmaceutical Companies are closer to marketing alternative means of birth control. A new contraceptive gel, developed by the Population council Research Centre in conjunction with Antares Pharma, will prevent pregnancy. By applying 3mg every day—to the arms, shoulders, abdomen or legs—women get the same protection as the pull, and with fewer side effects to boot.
Novartis Meningitis Vaccine Successful in Infants
Submitted by Rasik Sharma on Tue, 10/26/2010 - 07:36Novartis AG, a Swiss pharmaceutical company, has released data from a study indicating that the Menveo meningitis vaccine is effective in infants. Bacterial meningitis is a contagious illness that causes an infection of the membrane around the brain and spine. Approximately 50,000 deaths a year result from meningitis. Survivors can experience side effects such as brain damage and learning disabilities.
Aspirin can Improve Survival Chances in Men Suffering from Prostate Cancer
Submitted by Rasik Sharma on Tue, 10/26/2010 - 07:34A study that was recently conducted has shed some light on how men can cheat death, if they are suffering from prostate cancer. It has indicated that those men who’s, prostate cancer has not spread beyond the gland are less likely to die, if they consume aspirin.




























